Mr. Husseini received his undergraduate degree in Molecular Biology from Princeton University and MBA from the Wharton School at University of Pennsylvania. L. Andres Sirulnik, MD, PhD joined Regeneron in 2020 and serves as Senior Vice President, Translational and Clinical Sciences, Hematology, leading strategic program direction and clinical sciences work for our early- and late-stage oncologic hematology and late-stage non-oncology hematology portfolios. He received his AB in Biochemical Sciences from Princeton University and his MD-PhD in Biochemistry and Molecular Biophysics from Columbia University. With over 30 years global experience, Mr. McCowan leads the company’s IT organization and is responsible for global IT strategy supporting Research, Commercial, Cyber Security and Enterprise operations. Ms. Kowal also served as Vice President, Clinical Operations, on the clinical research organization side of the industry at a number of biotech organizations in a variety of clinical research roles early in her career. Industrial Operations and Product Supply at Regeneron Pharmaceuticals Before joining Regeneron, she was Vice President, Corporate Affairs for R&D and Strategy at Pfizer Inc. From 2008 to 2015, Dr. Herman was one of only three pharmaceutical industry members on the Executive Committee of the Biomarkers Consortium, a program within the Foundation for the National Institutes of Health. In 2008, Mr. Ryan retired as the Chairman and Chief Executive Officer of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. Randy Soltys, PhD, joined Regeneron in 2011 and now serves as Senior Vice President, Drug Safety and Pharmacometrics, where he is responsible for the Toxicology, Pathology, Preclinical PK/PD and Clinical and Quantitative Pharmacology organizations. Find Regeneron Pharmaceuticals jobs on Glassdoor. He also serves on the Boards of Trustees of The Rockefeller University and the Howard Hughes Medical Institute. Maya Bermingham, JD, joined Regeneron in 2015 and serves as Senior Vice President, Public Policy and Government Affairs. If using Safari, Quicktime is required. Prior to Inova, Ms. Paull was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Israel Lowy, MD, PhD, joined Regeneron in 2010 as Vice President, and now serves as Senior Vice President, Translational Sciences and Oncology. Apply for District Manager - Pulmonology Sales-Midwest job with Regeneron Pharmaceuticals in Chicago, IL, United States. Regeneron Inc employees with the job … Apply for general-and-administrative jobs at Regeneron. Beth F. Holly joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Most recently she was VP, Global Head of DE&I at Zendesk. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Dr. Reinertsen started her biotech career at Millennium Pharmaceuticals (now Takeda Oncology) where she held positions of increasing responsibility in business development. John Lin, MD, PhD, joined Regeneron in 2016 and oversees the preclinical bispecific antibody research work in Research and Development across all disease areas. Dr. Lowy is a licensed physician and has been board certified in internal medicine and infectious diseases. He has prior experience in healthcare industry-focused venture capital and investment banking roles, as well as serving as an audit senior at KPMG. He served as Chairman of the Board from 1990 through 1994. She holds a BS in Biology from the State University of New York at Binghamton and an MS in Neuroscience from New York University. Ms. Bermingham and her Washington, DC-based team play a critical role in helping Regeneron shape and maintain its industry-leading reputation among governmental stakeholders. Dr. Schleifer, together with Dr. Yancopoulos, has grown Regeneron from a tiny startup into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine and eight FDA-approved medicines. Huda Y. Zoghbi, MD, joined the board in 2016. She was named Woman of the Year by the Healthcare Businesswomen's Association in 2004, and named Business Leader of the Future by CNBC/Wall Street Journal in 2005. first round is hirevue video interview, all behavioral questions, about self-introduction, why regeneron, coursework and experience relative to internship, teamwork experience, and other questions.next round interview is interview with manager. Mr. Our robust research and development engine allows us to discover therapies that could have a profound impact on patient health. He received his BS in Biochemistry and Cell Biology from the University of California, San Diego, and his MD from Harvard Medical School. Learn about Regeneron culture, salaries, benefits, work-life balance, management, job security, and more. Gregory Geba, MD, PhD, joined Regeneron in 2013 and serves as Senior Vice President of the Global Development Scientific Council, a group that provides senior scientific input to Regeneron’s therapeutic portfolio of programs. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia; he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology. He has held leadership positions of increasing responsibility in Quality, Regulatory Affairs, Program Management and Manufacturing across biological, small molecule and medical device platforms. George L. Sing has been a Director of the company since January 1988, during which time he also held the position of Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. Dr. Baras received his BS, MBA and MD from Duke University. He earned his BS from Virginia Polytechnic Institute and State University. To achieve our mission to repeatedly bring important new medicines to patients with serious diseases, we remain committed to running our business responsibly and operating with the highest standards of integrity. Dr. Braunstein received his BS in Medicine and his MD from Northwestern University. Prior to joining Prudential, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank, where he also ran Chase's worldwide retail bank. Dr. Yancopoulos is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. McNay earned her BS in Chemical Engineering from the University of Delaware and her MS and PhD in Chemical Engineering from the University of Virginia. Prior to joining Regeneron, Ms. Holly spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. Ms. McCourt began her career and spent 12 years at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College. He is a physician-scientist with decades of experience in design, execution and analysis of clinical trials. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London). Mr. Van Plew received his MS in Chemistry from Penn State University and his MBA from Michigan State University. 247jobseeker Friday, 19th Feb 2021. Prior to joining Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. 123 Regeneron jobs available in Rensselaer, NY on Indeed.com. Carver earned his BS in Chemical Engineering from the University of Nevada, Reno and his PhD in Chemical Engineering from Iowa State University. Mr. McCowan previously worked at international organizations including Amgen, Artemis International, Computer Science Corporation and Lockheed. Before that, he was Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine. Ms. Gilooly earned a BS in Biology from the University of Massachusetts. The average Regeneron salary ranges from approximately $50,000 per year for Warehouse Worker to $293,497 per year for Senior Clinical Manager. A cookie can, amongst other things, track the web pages you visit and the options you use. $150K. A certified DE&I professional, Ms. Pillai received her BBA from KS School of Management and MBA from Symbiosis International Business School, India. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception, and acted as Chairman of the Board from 1990 through 1994. Continue Reading Before this, Dr. Reinertsen served as the Vice President of Corporate Development at Vertex Pharmaceuticals. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's seven FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene® and VelocImmune®. Niall O’Leary joined Regeneron in 2012 and serves as Senior Vice President and Site Head of IOPS Raheen. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Dr. Coles has been a director of McKesson Corporation since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors. How does this position fit into your career goals? He completed his post-doctoral studies at the University of Pennsylvania. Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs, Global Patient Safety. Salaries at Regeneron Inc range from an average of $56,988 to $166,375 a year. Ms. Tegan received her BS and MBA from Iona College. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. . Dr. Thurston received his BS in Physics at Yale University and his PhD in Biophysics from the University of British Columbia. Before joining Regeneron, Dr. Sirulnik was Chief Medical Officer at Merus N.V., a clinical-stage immuno-oncology company. Gonzalo Merino, PhD, JD, joined Regeneron in 2013 and now serves as Senior Vice President and Chief Intellectual Property Counsel. Regeneron Pharmaceuticals-Tarrytown, New York Manager, Site Budgets. He completed his medical residency at North Shore Long Island Jewish (LIJ) Health System and conducted post doctorate work at Columbia University. Andrew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics and is now Executive Vice President of Research. Dr. Tessier-Lavigne was appointed as the President of Stanford University in September 2016. He has held leadership roles in Quality, Validation, Regulatory, Internal Manufacturing and Engineering. Dr. Sirulnik is a licensed physician, formerly practicing at Dana-Farber Cancer Institute and Brigham and Women’s Hospital and was a fellow in hematology/oncology at Mount Sinai Health System. She has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science, and has been awarded numerous recognitions for her work, including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. She also previously served as Public Relations Officer at the American Red Cross Biomedical Services. Deborah Tegan joined Regeneron in 2006 and serves as Senior Vice President, Strategic Sourcing and Procurement. Join our team and help turn science into life-changing medicine. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons. Prior to joining Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as Executive Vice President and Chief Scientific Officer. Dr. Bassler received her BSc from the University of California, Davis, and her PhD in Biochemistry from Johns Hopkins University. Find out what works well at Regeneron from the people who know best. Gavin Thurston, PhD, joined Regeneron in 2001 initially to study the interaction of the VEGF signaling pathway with other angiogenic pathways and to target these pathways for the treatment of cancer. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Prior to joining Regeneron, she was Chief Business Officer of Constellation Pharmaceuticals.